Fundraising Fox
CRISPR QC
San Diego, US · Founded 2021 · Delaware corporation · 11 employees on LinkedIn · 3 known investors
Find your way into CRISPR QC
Sign up to see every warm intro you have to CRISPR QC
- Paths you didn't know you had: your email and LinkedIn already hold routes to the CRISPR QC team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
CRISPR QC develops the CRISPR Analytics Platform, a graphene-based biosensor system that provides real-time quantitative kinetic measurements of RNP formation, DNA target binding, and CRISPR-Cas cleavage activity. It serves gene-editing discovery, development, and manufacturing teams to pre-screen gRNA efficiency and de-risk experiments before costly downstream sequencing and screening.
Founders & leadership
RB
Ross BundyChief Executive OfficerRoss Bundy is Chief Executive Officer of Crisprqc, which develops a graphene-based CRISPR biosensor platform for gene-editing applications. He previously co-founded and scaled Cardea Bio Inc. and has over six years of biotechnology experience.
KA
Kiana AranNamed on SEC filing
MH
Michael HeltzenNamed on SEC filing
Board
GB
George BonarosBoard director
PG
Paul GrintBoard director
TR
Toby RichardsonBoard director
CY
Investors · 3
Reported raises · per SEC filings
Form D private placements$4.8M disclosed across 2 rounds · 2022–2024
▶$3.9MraisedApr 2025 · 14 investors · BiotechnologyRule 506(b)
▶$3.9MraisedApr 2025 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ross BundyExecutive Officer, Director
- George BonarosDirector
- Paul GrintDirector
- Kiana AranDirector
- Toby RichardsonDirector
- Chris YooDirector
- Offering amount
- $10M
- Amount sold
- $3.9M
- Minimum investment
- $5K
- First sale
- Jan 2024
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$885KraisedMar 2022 · 7 investors · BiotechnologyRule 506(b)
▶$885KraisedMar 2022 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael HeltzenDirector
- Ross Helgren BundyExecutive Officer
- Kiana AranDirector
- Offering amount
- $4M
- Amount sold
- $885K
- First sale
- Mar 2022
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
SynthegoSynthego develops CRISPR gene-editing and molecular diagnostics products, including custom CRISPR editors in mRNA or protein formats, base editors, and cell-free protein and RNA production systems. It serves researchers and cell and gene therapy developers in the biotechnology industry.
CRISPRCRISPR Therapeutics is a biotechnology company developing gene-based medicines using CRISPR/Cas9 gene-editing technology. It is led by a management team, board of directors, and scientific founders from the biotech and pharmaceutical industries.
OupOxford University Press (OUP) provides dictionary data, language datasets, and lexical content in over 60 languages to power digital literacy tools, educational software, gaming platforms, and media experiences. The company works across reading apps, word games, quiz shows, and broadcast media to expand access to language learning and comprehension.
Companies working in the same space as CRISPR QC.
Frequently asked questions
- What does CRISPR QC do?
- CRISPR QC develops the CRISPR Analytics Platform, a graphene-based biosensor system that provides real-time quantitative kinetic measurements of RNP formation, DNA target binding, and CRISPR-Cas cleavage activity. It serves gene-editing discovery, development, and manufacturing teams to pre-screen gRNA efficiency and de-risk experiments before costly downstream sequencing and screening.
- Who are CRISPR QC's investors?
- CRISPR QC's investors include BioBrit, Serra Ventures, Suncoast Ventures.
- How much funding has CRISPR QC raised?
- CRISPR QC has disclosed $4.8M raised across 2 rounds.
- Where is CRISPR QC headquartered?
- CRISPR QC is headquartered in San Diego, US.